Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria V. Savkina has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of the current state of pharmaceutical development of anti-staphylococcal prophylactic drugs

    by Irina A. Builova, Maria V. Savkina, Lidiya V. Sayapina, Maxim A. Krivykh, Yury I. Obukhov, Саяпина Лидия Васильевна, Кривых Максим Андреевич, Обухов Юрий Иванович

    Infection caused by Staphylococcus aureus is the most common infection leading to the development of serious complications in humans. S. aureus is among the highly lethal bacteremia-associated pathogens with a mortality rate of approximately 18% in industrial countries; in developing countries, the rate is even higher, up to 27%. One of the most striking and challenging aspects of clinical manifestations caused by S. aureus is the ability of the bacterium to develop resistance to antibiotics. The development of alternative treatment options for staphylococcal infection is urgently needed. The use of immunotherapy and immunoprophylaxis to activate the anti-infection immune response in patients should be considered as a promising direction. Objective: to analyze the main trends in the development of vaccines aimed at the prevention of S. aureus infection and its virulence factors. The present review discusses vaccine development in recent years aimed at preventing infection caused by S. aureus. Particular attention is paid to pathogenicity factors (such as capsule, surface proteins and enzymes) that may be useful for the development of new candidate vaccines or immune therapeutics. In recent years, numerous clinical trials of candidate vaccines based on different antigens, taking into account particularly relevant S. aureus pathogenicity factors that influence morbidity, have not been successful due to their low efficacy or insufficiently substantiated safety (development of adverse events). One of the most important factors constraining vaccine development is the lack of successful translation of vaccine protective activity, which is observed in preclinical studies in experimental models but not confirmed in clinical trials. Therefore, according to numerous researchers, the use of multiple antigens in vaccine formulations should be considered with the focus on different mechanisms of S. aureus pathogenicity and the use of adjuvants.


  • Open Access

    Promising pharmaceutical development of vaccines for the prevention of meningococcal infection

    by Maria V. Savkina, Lidiya V. Sayapina, Maxim A. Krivykh, Yury I. Obukhov, Саяпина Лидия Васильевна, Кривых Максим Андреевич, Обухов Юрий Иванович

    Meningococcal infection (MI) refers to anthroponoses; is an acute infectious disease with an aerosol transmission mechanism, characterized by various forms of the infectious process: from local (nasopharyngitis) and asymptomatic infections to generalized forms of invasive infection with the development of meningococcemia and meningitis. The causative agent of MI is meningococcus (Neisseria meningitidis) that belongs to the pathogen risk group 2. Preventive vaccination against MI is included in the calendar of preventive vaccinations according to epidemic indications. The problem of MI retains a great medical and social significance for Russian health care due to the continuing high rates of associated mortality, disability, high costs of treatment and rehabilitation. Vaccines against five of the six main N. meningitidis serogroups have been registered worldwide. Serogroup X vaccine is under development. Recently, there has been an increase in the heterogeneity of the meningococcal population due to serogroups W, Y, and X. The polysaccharide vaccines developed in Russia have restrictions on their use, and there is no full-cycle production of meningococcal conjugate vaccines in the Russian Federation. Given the above, the development and registration of new vaccines against MI is an urgent task. The purpose of this work is to analyze the current state of development of vaccines for MI prevention. Currently, depending on the production technology, the following types of meningococcal vaccines are available: polysaccharide, conjugated, based on outer membrane vesicles (OMV), protein and based on synthetic polysaccharides. Serogroup-targeted meningococcal vaccines are effective in reducing the public health burden of invasive MI. Polysaccharide conjugate and protein/OMV vaccines are among the most promising vaccines for most invasive meningococcal serogroups. In modern conditions, with the progress in technologies for future polysaccharide conjugate vaccines, new opportunities are opening up for the use of such approaches as chemical/enzymatic synthesis, improved characteristics of the carrier protein, and site-specific conjugation. The development of a single vaccine against the main invasive meningococcal serogroups, rather than its individual antigenic variants, does not lose its relevance. It is timely to develop in the near future a vaccine against N. meningitidis serogroup X, which was previously a rare cause of sporadic meningitis, but has caused outbreaks in various African countries in 20062010 and in recent years.

  • Open Access

    Botulinum toxin preparations: areas for improvement and issues of standardisation

    by M. V. Savkina, M. A. Krivykh, L. V. Sayapina, Yu. I. Obukhov, V. P. Bondarev, Ю. И. Обухов

    Scientific relevance. Botulinum toxin preparations are a good example of using a deadly toxin as a unique therapeutic agent. However, there are many unresolved issues related to biotechnology, biological activity, interchangeability, and standardisation of botulinum toxin preparations. Aim. To review current opportunities for improving therapeutic botulinum toxin preparations.Discussion. This review covers botulinum toxin type A preparations and unresolved issues related to them. In the absence of international non-proprietary names recommended by the World Health Organisation or by the Board of the Eurasian Economic Commission, domestic and imported botulinum toxin type A preparations approved in Russia have only similarity-based grouping names. In addition, manufacturers name botulinum toxin preparations at their discretion. Therefore, classifying these preparations under a common nomenclature is essential for clear identification, adequate selection, and correct prescription. Several studies have shown significant variability across botulinum toxin type A preparations. Due to the identified differences in qualitative and quantitative characteristics, botulinum toxin type A preparations cannot be considered similar, which raises the issue of their interchangeability and bioequivalence. To resolve this issue, a unified classification and naming system for botulinum toxin preparations should be established and documented in regulatory standards. According to the literature, manufacturers of botulinum toxin preparations use in-house reference standards. Hence, the same activity unit resulting from toxicity and efficacy studies may express a different protein load for each botulinum toxin preparation. Keeping that in mind, the authors discuss the development of a single international potency standard for existing and pipeline botulinum toxin type A preparations. Conclusions. The article describes novel pharmaceutical compositions containing botulinum toxin, including those in late development. Summarised data from clinical studies on the safety, efficacy, and cost-effectiveness of botulinum toxin type A preparations can guide prescribing decisions.

  • Open Access

    Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection

    by M. V. Savkina, M. A. Krivykh, N. A. Gavrilova, L. V. Sayapina, Yu. I. Obukhov, V. A. Merkulov, V. P. Bondarev, Ю. И. Обухов

    Streptococcus pneumoniae infection is the most common cause of high morbidity and mortality among children under 5 years of age, immunocompromised people, and the elderly. Despite significant success, the approved pneumococcal conjugate and polysaccharide vaccines are of limited efficacy, providing protection against a small fraction of the known pneumococcal serotypes. The rapid spread of multidrug-resistant strains exacerbates the global challenge of treating infection caused by S. pneumoniae. At the same time, the emerging new strains dictate the need to include new serotypes into vaccines. In view of this, further improvement of vaccines for the prevention of pneumococcal infections is an urgent task. The aim of this study was to review advances in the development of polysaccharide, conjugate, whole-cell pneumococcal vaccines, as well as vaccines based on protein antigens and vaccines with an antigen delivery system. Genomics and proteomics data have helped to improve approaches to the creation of polysaccharide and protein-based vaccines, as well as whole-cell vaccines with the potential for population prophylactic coverage against various pneumococcal serotypes that are not included in the licensed pneumococcal vaccines. The method of antigen delivery to the cell is of great importance in the development of vaccines. The most promising strategy for improving pneumococcal vaccines is the creation of vaccines based on bacterium-like or synthetic particles carrying several antigens, including pneumococcal surface proteins. In conclusion, it should be noted that top-priority vaccines are those that provide a wide range of protection against circulating pneumococcal serotypes and, in addition to eliciting a systemic immune response, also induce local immunity.

  • Open Access

    The Current Use of Biomedical Cell Products for Cancer Treatment

    by E. A. Ustyugova, M. V. Savkina, A. A. Goryaev, V. P. Bondarev, V. A. Merkulov, Е. В. Мельникова

    Применение биомедицинских клеточных продуктов для лечения онкологических заболеваний


  • Open Access

    DNA and RNA Vaccines: Current Status, Quality Requirements and Specific Aspects of Preclinical Studies

    by A. A. Goryaev, M. V. Savkina, Yu. I. Obukhov, V. A. Merkulov, Yu. V. Olefir, Ю. И. Обухов

    This review focuses on DNA and RNA vaccines whose potential use was first considered at the end of the 20th century. However, not a single bacterial plasmid-based or mRNA vaccine has been used since that time in public healthcare for the prevention of infectious diseases. Nevertheless, vaccines containing recombinant nucleic acids as the active ingredient still attract interest due to the possibility of rapid development, low-cost production, safety of the technology and the potential to activate cellular and humoral immunity. Recent technological advances have largely overcome the problems of low immunogenicity, instability, and difficulties with the delivery of DNA and RNA vaccines in humans. The aim of this review was to present the main strategies of development of DNA and RNA vaccines designed to prevent infectious diseases, and to summarise requirements for the quality control and preclinical studies. The article examines the general principles of creation of plasmid vectors encoding protective antigens. It describes new technologies used in the creation of DNA vaccines with plasmids encoding an attenuated virus genome (iDNA and PPLAV), and RNA vaccines based on mRNA and self-amplifying RNAs. The article presents current regulatory requirements for the choice of quality parameters to be tested and the general principles of preclinical studies of DNA and RNA vaccines.


  • Open Access

    Genome-Editing and Biomedical Cell Products: Current State, Safety and Efficacy

    by A. A. Goryaev, M. V. Savkina, K. M. Mefed, V. P. Bondarev, V. A. Merkulov, V. V. Tarasov

    Advances in ex vivo technologies of human genome editing have made it possible to develop new approaches to the treatment of genetic, oncological, infectious and other diseases, which may involve the use of biomedical cell products. However, despite the rapid development of these technologies and a large number of clinical trials conducted in many countries around the world, only 4 products (Strimvelis, Zalmoxis, Kymriah and Yescarta) containing ex vivo genetically modified human cells are authorised for use in the European Union and the United States of America. This paper considers three promising technologies (ZFN, TALEN and CRISPR) that allow for easy and effective editing of the genome at the sites of interest, thereby creating a platform for further development of the genetic engineering of human cells. It describes the technology of engineering chimeric antigen receptors (CARs). It also provides data on the efficacy and safety of the approved products: Strimvelis which contains autologous CD34+ cells transduced ex vivo with a retroviral vector containing adenosine deaminase gene, Zalmoxis which contains modified allogeneic T-cells, and two products: Kymriah and Yescarta which contain autologous T-cells with CARs to CD19 antigen, intended for the treatment of CD19+ hematological malignancies.


  • Open Access

    International Approaches to Regulation of Medicinal Products Containing Viable Human Cells

    by Е. В. Мельникова, A. A. Goryaev, M. V. Savkina, O. V. Merkulova, A. A. Chaplenko, O. A. Rachinskaya, I. S. Semenova, G. A. Trusov, V. A. Merkulov

    The intensive development of cellular technologies stipulates the introduction at the global level of medicinal products based on viable human cells, which in most countries are referred to as biomedical cell products. The authors conducted a comparative analysis of the regulatory framework in different countries and determined special aspects of regulation of cell therapy products (analogues of biomedical cell products). Some countries have mechanisms for priority review of cell therapy products for marketing authorization, such as accelerated assessment, accelerated approval, or conditional marketing authorisation. These mechanisms are currently absent in Russia, because of the novelty of the regulatory framework, and the biological properties of innovative cell products. Biomedical cell products are regarded as a separate class of medicinal products in Russia, they are not treated as biologicals and are regulated by the Federal Law No. 180-FZ «On Biomedical Cell Products» of June 23, 2016. The main difference in regulation of cell-based products in the Russian Federation is the principle of unified requirements for marketing authorisation of autologous, allogeneic, and combined biomedical cellular products, and the absence of the «hospital exemptions» mechanism that exists in many countries. This mechanism allows prescription and use of personalised autologous medicines produced in the laboratory of a medical institution for a particular patient.


  • Open Access

    Human Mitochondrial Transcription Revisited

    by Dmitry Litonin, Marina Sologub, Yonghong Shi, Maria Savkina, Michael Anikin, Maria Falkenberg, Claes M. Gustafsson, Dmitry Temiakov